Hemogenyx raises £570,000 and Director's Dealing
Rhea-AI Summary
Hemogenyx Pharmaceuticals (LSE:HEMO) has successfully raised £570,000 through an allotment of 316,667 new ordinary shares at 180p per share, representing a premium to the market price. The shares were initially subscribed by CEO Vladislav Sandler and will be directed to a small group of investors.
The funding will support the continuation of the company's Phase I clinical trials for HG-CT-1, a Chimeric Antigen Receptor T-cell therapy targeting relapsed/refractory acute myeloid leukemia in adults. The investors will also receive one-for-one warrants exercisable for 36 months at 180p.
Following admission, expected around September 4, 2025, the company's total issued shares will be 5,043,896. The premium-priced fundraising reflects investor confidence in Hemogenyx's progress and long-term prospects.
Positive
- Raised £570,000 at a premium to market price, indicating strong investor confidence
- Early Phase I trials of HG-CT-1 show promising safety and potential efficacy signals
- Additional warrant coverage provides potential for future capital at 180p per share
Negative
- Relatively small funding amount may require additional capital raises in the future
- Complex share issuance structure required due to prospectus requirements
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UK / ACCESS Newswire / August 26, 2025 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Hemogenyx Secures
Introduction
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised gross proceeds of
The net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ("HG-CT-1"), aimed at treating relapsed/refractory acute myeloid leukemia in adults ("R/R AML"). As shareholders will be aware, the Company has made significant strides in its Phase 1 clinical trial of HG-CT-1, with early trials supporting growing confidence in both safety and potential efficacy.
Issuance of the New Ordinary Shares
The Company is currently unable to issue and admit New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus.
Consequently, this fundraise involves the agreement by Vladislav Sandler, CEO and director of the Company, to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.
Following allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to a small group of individual investors who made an approach wishing to make a new investment in the Company.
Warrants
Concurrent with the purchase of the New Ordinary Shares, the new investor group will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 180p ("Exercise Price"), subject to adjustment in certain circumstances as set out in the warrant instrument including a reset of the Exercise Price if the Company completes a share issuance (or other transaction granting rights to subscribe for equity securities) during the Exercise Period at a price lower than the Exercise Price.
Total Voting Rights
Application will be made for the 316,667 New Ordinary Shares, which will rank pari passu in all respects with the existing Ordinary Shares of the Company, to be admitted to the FCA official list and to trading on the equity shares (transition) category of the Official List maintained by the FCA and to trading on the main market for listed securities of the LSE, which is expected to occur on or around 8.00 a.m. on 4 September 2025 ("Admission").
Upon Admission, the total number of issued shares and the total number of voting rights in the Company will be 5,043,896.
The above figure of 5,043,896 should be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The Company will keep the market informed of future developments as trials proceed.
Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:
"We are pleased to have attracted funding from a small group of dedicated investors at a premium to the market price. This reflects investors' confidence in the progress made by the Company to date and in its long-term prospects. The fact that the raise was completed at a premium to the market price demonstrates this confidence and shows that the investors see considerable upside potential in our share price as we advance HG-CT-1 through clinical development".
UK Market Abuse Regulation (UK MAR) Disclosure
Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. The person responsible for arranging for the release of this announcement on behalf of Hemogenyx Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer & Co-Founder.
Director's Dealing Notification
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Vladislav Sandler | ||||
2. | Reason for the Notification | |||||
a) | Position/status | PDMR | ||||
b) | Initial notification / Amendment | Initial notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Hemogenyx Pharmaceuticals plc | ||||
b) | LEI | 2138008L93GYU5GN6179 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of | ||||
Identification Code | GB00BQVXM815 | |||||
b) | Nature of the transaction | Off Market Allotment | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: Aggregated volume Price | 316,667 Ordinary Shares 180 pence per Ordinary Share | ||||
e) | Date of the transaction | 27 August 2025 | ||||
f) | Place of the transaction | London | ||||
Enquiries:
Hemogenyx Pharmaceuticals plc | |
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | |
Peter Redmond, Director | |
SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
Matthew Johnson, Vadim Alexandre, Adam Cowl | |
Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
Lucy Williams, Duncan Vasey, Charles Goodfellow |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View the original press release on ACCESS Newswire
FAQ
What is the purpose of Hemogenyx's £570,000 fundraising in August 2025?
How many new shares did Hemogenyx (LSE:HEMO) issue in this fundraising?
What is the significance of Hemogenyx's share price premium in this fundraising?
What will be Hemogenyx's total number of shares after this issuance?
How is CEO Vladislav Sandler involved in this fundraising?
